Repare Therapeutics Inc (RPTX)

$3.9

-0.04

(-1.02%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $3.90
    $4.29
    $3.90
    downward going graph

    0.0%

    Downside

    Day's Volatility :9.09%

    Upside

    9.09%

    downward going graph
  • $2.98
    $13.85
    $3.90
    downward going graph

    23.59%

    Downside

    52 Weeks Volatility :78.48%

    Upside

    71.84%

    downward going graph

Returns

PeriodRepare Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
19.63%
6.4%
0.0%
6 Months
-38.19%
6.0%
0.0%
1 Year
-63.38%
9.6%
0.0%
3 Years
-88.5%
14.8%
-19.4%

Highlights

Market Capitalization
167.2M
Book Value
$5.47
Earnings Per Share (EPS)
-1.1
Wall Street Target Price
14.67
Profit Margin
-46.69%
Operating Margin TTM
20.64%
Return On Assets TTM
-14.75%
Return On Equity TTM
-18.91%
Revenue TTM
97.9M
Revenue Per Share TTM
2.32
Quarterly Revenue Growth YOY
822.8999999999999%
Gross Profit TTM
15.1M
EBITDA
-68.7M
Diluted Eps TTM
-1.1
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.32
EPS Estimate Next Year
-3.21
EPS Estimate Current Quarter
0.02
EPS Estimate Next Quarter
-0.88

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Repare Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 276.15%

Current $3.90
Target $14.67

Technicals Summary

Sell

Neutral

Buy

Repare Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Repare Therapeutics Inc
Repare Therapeutics Inc
10.8%
-38.19%
-63.38%
-88.5%
-87.34%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Repare Therapeutics Inc
Repare Therapeutics Inc
NA
NA
NA
-2.32
-0.19
-0.15
NA
5.47
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Repare Therapeutics Inc
Repare Therapeutics Inc
Buy
$167.2M
-87.34%
NA
-46.69%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Repare Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 2.15M → 52.40M (in $), with an average increase of 79.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -28.03M → 13.16M (in $), with an average increase of 313.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 59.9% return, outperforming this stock by 123.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 200.6% return, outperforming this stock by 289.1%

Institutional Holdings

  • Bvf Inc

    24.35%
  • Orbimed Advisors, LLC

    7.83%
  • Blue Owl Capital Holdings LP

    7.36%
  • ARK Investment Management LLC

    6.37%
  • Deep Track Capital, LP

    6.32%
  • Versant Venture Management LLC

    6.24%

Company Information

repare therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. its approach integrates insights from several fields of cell biology including dna repair and synthetic lethality. repare’s platform combines a proprietary, high throughput, crispr‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics. the company is backed by leading global healthcare investors including founding investor versant ventures and mpm capital. for additional information, please visit www.reparerx.com.

Organization
Repare Therapeutics Inc
Employees
179
CEO
Mr. Lloyd Mitchell Segal
Industry
Health Technology

FAQs